A Shanghai-based venture capital/private equity firm manages both USD and RMB denominated funds. The firm invests in Series A rounds at $1-2M, though its sweet spot is investing $10-15M in Series B/C rounds. The firm works closely with local provincial Chinese governments, allowing them the ability to bring technology successfully into the Chinese market. The firm will generally not invest in the seed stage and seeks opportunities globally.
The firm invests in pharmaceuticals and Class II medical devices, including an interest in 505(b)(2) repurposed compounds, as well as healthcare-related industries. The firm is interested in all therapeutic areas and in early to mid-development stage companies. The firm focuses on unmet medical needs with a China market potential.
The firm does not have management team requirements. The firm will typically take a board seat post-investment, and has the capability to lead and co-invest.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply